The combination of CXCL5 antibody, 1400 W or GM-CSF antibody with anti-PD-L1 mAb reduced primary tumour growth and RFP-positive LLCs in lungs and prolonged the survival of cancer bearing mice compared with PD-L1 antibody alone, indicating that MDSC depletion can enhance the efficacy of immunotherapy (Fig. 6d and Supplementary Fig. 5A, B, E, F). Here, CXCL5 is linked to cancer.